Skip to content.

Spotlight

Featured

Perspectives
Why we invested in OpenTrade
1 / 7
Read more
Perspectives
Why we invested in Infact
2 / 7
Read more
Perspectives
Why we invested in trumpet
3 / 7
Read more
Perspectives
Why we invested in Instinct
4 / 7
Read more
Perspectives
Why we invested in Treefera
5 / 7
Read more
Perspectives
Why we invested in Oriole Networks
6 / 7
Read more
Perspectives
Why we invested in Gridcog
7 / 7
Read more

Perspectives
Simon Goldman on transforming hard science into global impact – Podcast

Simon Goldman on transforming hard science into global impact

Read the article >
Perspectives
Our journey with Odin Vision

Our journey with Odin Vision

Read the article >
Perspectives

A computing impasse – the investments we make now will define our future

Read the article >
Perspectives
What's happening in biotech?

On not downclimbing – the prospects for early stage biotech remain bright

Read the article >
Perspectives

Why we invested in Carbon Re?

Read the article >
Perspectives

Bringing immuno-oncology cell therapies to the masses – are we (nearly) there yet?

Read the article >
Perspectives
Will the boom last?

A window to the past: is the investment boom in biotech going to last?

Read the article >
Perspectives
On the UK biotech public market

Over the Hill and (still) far away for UK biotechs

Read the article >
Perspectives

Why you should consider manufacturing from the start of the biotech R&D process

Read the article >
Perspectives
Platform technologies: going deep to go wide

Platform technologies: going deep to go wide

Read the article >
Perspectives
How to fund biotechs?

An evolution in early stage gene therapy funding models

Read the article >
Perspectives

An evolution in early stage gene therapy funding models

Read the article >